Try our Advanced Search for more refined results
Life Sciences
- 
									September 11, 2025
									3rd Circ. Won't Toss Talc Co. Whittaker Clark & Daniels' Ch. 11Defunct talc supplier Whittaker Clark & Daniels properly filed for Chapter 11 protection in 2023 and its bankruptcy case should not be dismissed, the Third Circuit has ruled, siding against talc claimants who argued the company already being in receivership precluded it from filing for bankruptcy. 
- 
									September 11, 2025
									7th Circ. Backs $183M FCA Award Over Eli Lilly Drug RebatesThe Seventh Circuit refused on Thursday to unwind a whistleblower's $183 million trial win against Eli Lilly in a false claims case targeting more than a decade of drug rebate miscalculations, saying a jury reasonably found that the company knowingly "hid the truth" about how much it charged for Medicaid-covered drugs. 
- 
									September 11, 2025
									Dental Supply Co.'s $84M Price-Fixing Deal Gets Final OKDental supply company Dentsply Sirona Inc. and its investors have gotten final approval for an $84 million deal resolving consolidated shareholder class action claims that the company hurt investors by concealing a price-fixing scheme and a distributor's inventory buildup. 
- 
									September 11, 2025
									Freshfields, Kirkland Advise On Advent's $4.7B Zentiva SaleEuropean generics pharmaceutical company Zentiva will be sold by private equity firm Advent to U.S.-based GTCR, Advent announced Thursday. 
- 
									September 11, 2025
									Zeiss Secures $785K In X-Ray Patent Trial Against SigraySigray Inc. is on the hook for $785,000 in damages after a finding in California federal court this week that it infringed X-ray imaging patents owned by Carl Zeiss X-Ray Microscopy Inc., but the jury also found that Sigray's infringement was not willful and refused to award any lost profits. 
- 
									September 11, 2025
									Cooley-Led LB Pharmaceuticals Raises Upsized $285M IPOLB Pharmaceuticals, a clinical-stage biopharma company developing therapies for a number of neuropsychiatric diseases, hit the public markets on Thursday after raising $285 million in an upsized initial public offering. 
- 
									September 10, 2025
									Fed. Circ. Won't Revisit Double-Patenting, Soda TM AppealsThe Federal Circuit on Wednesday declined to revisit its decisions in a trio of intellectual property cases, including one where it upheld an Acadia Pharmaceuticals Parkinson's disease drug patent and addressed double-patenting, and another deeming "Kist" and "Sunkist" soft drink marks confusingly similar. 
- 
									September 10, 2025
									Teleradiology Co. Seeks OK Of Award Nixing $2M Fraud ClaimAn Indian teleradiology company asked a Georgia federal court not to vacate an arbitral award that rejected a radiology provider's $2 million fraud claim against it, arguing that the arbitrator properly interpreted their longstanding vendor–vendee contract. 
- 
									September 10, 2025
									DexCom Beats Most Of Investors' Diabetes Device Sales SuitA California judge has trimmed a proposed class action from shareholders of glucose monitor manufacturer DexCom Inc. who allege they were damaged by the company's misrepresentations regarding its ability to keep up with growing demand, with the court determining the shareholders' complaint falls short in several instances. 
- 
									September 10, 2025
									Hydroxycut Maker Iovate Gets Ch. 15 Relief As Case Kicks OffA New York bankruptcy judge agreed Wednesday to temporarily stay creditor actions against Canadian dietary supplement business Iovate Health Sciences one day after the Hydroxycut maker sought Chapter 15 protection. 
- 
									September 10, 2025
									Chemical Co. Challenges $7.7M Tax Bill Over Foreign CreditsMultinational chemical manufacturer Huntsman is challenging a $7.7 million tax liability in the U.S. Tax Court, alleging that the IRS erred by not applying its Dutch holding company's deficit to its deemed paid foreign tax credits. 
- 
									September 10, 2025
									Medical Equipment Co. Settles County Claims In Opioid MDLMedical equipment company Henry Schein Inc. and its related entities have settled claims by Virginia counties brought against it in the sprawling national opioid litigation, according to a notice filed Wednesday. 
- 
									September 10, 2025
									Jones Day Adds Ex Fed. Prosecutor To SF Healthcare TeamJones Day is expanding its health care team, bringing in a former assistant U.S. attorney as of counsel in its San Francisco office. 
- 
									September 10, 2025
									Chinese Scholar Gets Time Served In Smuggling CaseA Michigan federal judge on Wednesday said more time in prison wasn't warranted in the case of a Chinese scholar accused of smuggling biological material into the U.S., finding the last three months she's spent in custody and the collateral damage done to her personal and professional life are sufficient punishment. 
- 
									September 10, 2025
									Splenda Maker Says Scientist's Counterclaims Are Too LateThe company behind artificial sweetener Splenda is urging a North Carolina federal court to deny a scientist's bid to amend her counterclaims in a suit over whether Splenda contains cancer-causing chemicals, saying her claims are either outside the statute of limitations or retreads of claims she already dropped. 
- 
									September 09, 2025
									4th Circ. Debates Whether 'Silence' In 340B Empowers StatesTwo states told a Fourth Circuit panel on Tuesday that "silence" in the law governing the federal government's drug discount program permits state enforcers to step in and regulate the delivery of those drugs to their communities. 
- 
									September 09, 2025
									CVS Says Takeda Tried To Block Heartburn Drug CompetitionDrugmaker Takeda Pharmaceutical Co. Ltd. and other entities engaged in a "horizontal conspiracy and agreement" to restrain competition in the U.S. market for the acid reflux drug Dexilant and its generic equivalents, CVS Pharmacy Inc. alleged in a complaint filed in California federal court Tuesday. 
- 
									September 09, 2025
									PTAB Leader Urges Specificity In Discretionary Denial BriefsThe Patent Trial and Appeal Board's acting chief judge urged litigants Tuesday to support the arguments they make in the board's new discretionary denial process with specific details about their cases, during a panel where lawyers expressed both frustration about and praise for the system. 
- 
									September 09, 2025
									Zantac Buyers Will Appeal Sanofi Dismissal From Conn. SuitHundreds of out-of-state purchasers of the heartburn drug ranitidine, the generic form of Zantac, have signaled plans to appeal a Connecticut judge's dismissal of negligent design claims against Sanofi-Aventis U.S. LLC, challenging the conclusion that they had no right to sue the company in the Constitution State. 
- 
									September 09, 2025
									Omni Must Pay Atty Fees Over 'Troubling' Conduct In FCA SuitA Massachusetts federal judge has ordered a medical practice to pay legal fees to a lab it accused of False Claims Act violations, ruling its claims were "clearly vexatious" because the provider knowingly ordered medically unnecessary tests to support its suit. 
- 
									September 09, 2025
									MAHA Report Calls For Increased Scrutiny Of Drug AdvertisingThe Trump administration on Tuesday pledged to ramp up federal oversight of drug advertising, update dietary guidelines and slash unnecessary regulations as part of its strategy to boost the health of America's children and curb the rise in childhood chronic disease. 
- 
									September 09, 2025
									Gilgo Beach DNA Evidence Ruling May Propel New MethodsA recent ruling from the New York judge overseeing the Gilgo Beach serial killer case finding that the newer DNA testing method known as whole genome sequencing clears rigorous admissibility standards is a laudable decision that could help solve cold cases, according to proponents of the technology. 
- 
									September 09, 2025
									Sandoz, Regeneron Settle Eye Drug Patent ClaimsSandoz Inc. and Regeneron Pharmaceuticals Inc. have reached a settlement to resolve patent claims Regeneron had asserted over a biosimilar alternative to its Eylea ophthalmic disorder drug. 
- 
									September 09, 2025
									Particle's Antitrust Battle With Epic: 3 Things To KnowEpic Systems Corp. must face allegations it violated federal law by attempting to monopolize a segment of the electronic health records market to the exclusion of competitor Particle Health Inc. Here's what you need to know about the case. 
- 
									September 09, 2025
									Roberts Pauses Foreign Aid Distribution For NowChief Justice John Roberts on Tuesday temporarily stayed a lower court's order requiring the Trump administration to release roughly $4 billion in frozen foreign aid while the U.S. Supreme Court considers a longer-term solution. 
Expert Analysis
- 
								
								What FCA Liability Looks Like In The Cybersecurity Realm  Two recent settlements highlight how whistleblowers and the U.S. Department of Justice have been utilizing the False Claims Act to allege fraud predicated on violations of cybersecurity standards — timely lessons given new bipartisan legislation introducing potential FCA liability for artificial intelligence use, say attorneys Rachel Rose and Julie Bracker. 
- 
								
								Foreign Sovereign Entities Should Heed 9th Circ. IP Ruling  After the Ninth Circuit recently held that four Chinese state-controlled companies were not immune from criminal indictment for alleged economic espionage, foreign sovereign-controlled entities should assess whether their operations and affiliation with their parent states qualify for sovereign immunity under the common law, say attorneys at Cleary. 
- 
								
								How Attorneys Can Become Change Agents For Racial Equity  As the administration targets diversity, equity and inclusion efforts and law firms consider pulling back from their programs, lawyers who care about racial equity and justice can employ four strategies to create microspaces of justice, which can then be parlayed into drivers of transformational change, says Susan Sturm at Columbia Law School. 
- 
								
								CMS Guidance May Complicate Drug Pricing, Trigger Lawsuits  Recent draft guidance from the Centers for Medicare & Medicaid Services proposes to expand the scope of what counts as the same qualifying single-source drug, which would significantly alter the timeline for modified drugs facing price controls and would likely draw legal challenges from innovator drug companies, say attorneys at Debevoise. 
- 
								
								Strategies For Litigating In The Unified Patent Court  Since opening its gates two years ago, the European Unified Patent Court has transformed the patent litigation landscape and global litigation strategies, but parties seeking to take advantage of the court's robust processes must be prepared for the front-loaded character of UPC proceedings, say attorneys at McDermott. 
- 
								Series Running Marathons Makes Me A Better Lawyer  After almost five years of running marathons, I’ve learned that both the race itself and the training process sharpen skills that directly translate to the practice of law, including discipline, dedication, endurance, problem-solving and mental toughness, says Lauren Meadows at Swift Currie. 
- 
								Series Law School's Missed Lessons: Supporting A Trial Team  While students often practice as lead trial attorneys in law school, such an opportunity likely won’t arise until a few years into practice, so junior associates should focus on honing skills that are essential to supporting a trial team, including organization, adaptability and humility, says Lucy Zelina at Tucker Ellis. 
- 
								
								Compliance Essentials To Mitigate AI Crime Enforcement Risk  As artificial intelligence systems move closer to accurately mimicking human decision-making, companies must understand how the U.S. Department of Justice might prosecute them for crimes committed by AI tools — and how to mitigate enforcement risks, say attorneys at Paul Hastings. 
- 
								Series Adapting To Private Practice: From US Attorney To BigLaw  When I transitioned to private practice after government service — most recently as the U.S. attorney for the Eastern District of Virginia — I learned there are more similarities between the two jobs than many realize, with both disciplines requiring resourcefulness, zealous advocacy and foresight, says Zach Terwilliger at V&E. 
- 
								
								Most-Favored Nation Drug Pricing Could Shake Up US Pharma  Recent moves from the executive and legislative branches represent a serious attempt to revive and refine the first Trump administration's most-favored-nations model for drug pricing, though implementation could bring unintended consequences for pharmaceutical manufacturers and will likely draw significant legal opposition, say attorneys at Morgan Lewis. 
- 
								
								The Ins And Outs Of Consensual Judicial References  As parties consider the possibility of judicial reference to resolve complex disputes, it is critical to understand how the process works, why it's gaining traction, and why carefully crafted agreements make all the difference, say attorneys at Pillsbury. 
- 
								Opinion Congress Must Restore IP Protection To Drive US Innovation  Congress should pass the RESTORE Patent Rights Act to enforce patent holders' exclusive rights and encourage American innovation, and undo the decades of patent rights erosion caused by the U.S. Supreme Court's 2006 decision in eBay v. MercExchange, says former Chief U.S. Circuit Judge Paul Michel. 
- 
								
								How Focus On Menopause Care Is Fueling Innovation, Access  Recent legislative developments concerning the growing field of menopause care are creating opportunities for increased investment and innovation in the space as they increase access to education and coverage, say attorneys at Kirkland. 
- 
								Opinion The BigLaw Settlements Are About Risk, Not Profit  The nine Am Law 100 firms that settled with the Trump administration likely did so because of the personal risk faced by equity partners in today's billion‑dollar national practices, enabled by an ethics rule primed for modernization, says Adam Forest at Scale. 
- 
								
								Neb.'s Cannabis Regulatory Void Poses Operational Risks  With the Nebraska Legislature recently declining to advance any cannabis legislation, leaving the state without a regulatory framework for voter-passed initiatives, the risks of operating without clear rules will likely affect patients, providers and caregivers, says John Cartier at Omnus Law.